drug resistance – Page 2

Plants, fungi, and antifungals: A little less talk, a little more action

mycolabadmin

Researchers propose looking at how plants communicate with fungi to discover new antifungal medicines. Plants send chemical signals to fungi, and understanding these signals could help us develop better treatments for fungal infections in humans and crops. By studying a simple yeast model, scientists found that plant molecules called strigolactones control fungal phosphate metabolism, suggesting they could become new drug targets.

Transcriptomics Insights into Targeting CK2 Complex in Cryptococcus neoformans: Implications for Large-Scale Antifungal Virtual Screening

mycolabadmin

Scientists studied how a fungus called Cryptococcus neoformans causes serious brain infections and found that disabling a specific protein complex (CK2) could be an effective treatment strategy. Using computer analysis of genetic data, they identified three existing drugs—amphotericin B, idarubicin, and candicidin—that could potentially target and kill this dangerous fungus. This research provides a foundation for developing better treatments for cryptococcal meningitis, a life-threatening infection that kills hundreds of thousands of people annually, especially those with weakened immune systems.

The impact of climate change on the epidemiology of fungal infections: implications for diagnosis, treatment, and public health strategies

mycolabadmin

Climate change is making it easier for dangerous fungi to grow and spread to new areas where people have never encountered them before. As temperatures rise and weather becomes more extreme, fungi are becoming resistant to our medicines, especially antifungal drugs used in both farming and hospitals. People living in poverty, displaced by natural disasters, and those without good healthcare access are most vulnerable to these infections. We need to act quickly by developing new treatments, improving diagnosis, reducing agricultural fungicide use, and strengthening healthcare systems in vulnerable communities.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Allergic bronchopulmonary mycosis caused by Scedosporium apiospermum: A case report

mycolabadmin

A 61-year-old woman developed a rare fungal infection in her lungs caused by Scedosporium apiospermum while undergoing cancer treatment. The infection caused persistent cough, mucus plugs in the airways, and high levels of immune cells called eosinophils. Doctors used genetic testing to identify the specific fungus and then treated her with corticosteroids and antifungal medications, which improved her condition significantly.

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers studied how Bunium persicum essential oil and two of its active components work together with the antifungal drug fluconazole to fight resistant Candida yeast infections. They found that cuminaldehyde, one of the oil’s main components, was particularly effective when combined with fluconazole and could trigger yeast cell death. These natural compounds could offer a promising new approach to treating fungal infections that have become resistant to standard medications.

Metabolic Patterns of Fluconazole Resistant and Susceptible Candida auris Clade V and I

mycolabadmin

Researchers used advanced chemical analysis to identify different compounds produced by a dangerous fungus called Candida auris that can cause serious infections. They compared fungal strains that were resistant to the antifungal drug fluconazole with those that were susceptible, finding that resistant strains produced different metabolites (chemical compounds) than susceptible ones. These findings could help doctors develop better treatments by identifying what makes this fungus resistant to current medications.

Methods for Overcoming Chemoresistance in Head and Neck Squamous Cell Carcinoma: Keeping the Focus on Cancer Stem Cells, a Systematic Review

mycolabadmin

Head and neck cancer is often resistant to chemotherapy because of cancer stem cells that survive treatment and cause recurrence. This review examined 31 studies on methods to overcome this resistance, finding that natural products like mushrooms (Ganoderma lucidum), plants (sulforaphane from broccoli, curcumin from turmeric), and synthetic compounds can enhance chemotherapy effectiveness when combined with traditional drugs. These approaches work by targeting the specific pathways that allow cancer stem cells to survive, potentially improving treatment outcomes while reducing required drug doses and side effects.

Analysis of Susceptibility and Drug Resistance of Antifungal Agents in Aspergillosis and Mucormycosis Patients: A Systematic Review

mycolabadmin

This comprehensive study analyzed how well five major antifungal drugs work against common disease-causing fungi like Aspergillus and Mucorales. Researchers reviewed 96 studies examining over 16,000 fungal samples to understand resistance patterns. The findings show that different fungi respond better to different drugs—for example, Aspergillus flavus responds well to voriconazole, while amphotericin B works best against other Aspergillus species. This information helps doctors choose the most effective treatments for fungal infections in vulnerable patients.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

This interview with Dr. John Perfect, a leading expert in fungal infections, discusses how antifungal treatments have evolved over his 48-year career. He explains that while fungal resistance is a concern, it’s less problematic than bacterial antibiotic resistance because fungi don’t spread resistance through plasmids. Dr. Perfect emphasizes the importance of newer, faster-acting antifungal drugs and combining drug therapy with immune system support to better treat serious fungal infections like cryptococcal meningitis and candidemia.

Research Keyword: drug resistance